Page 43 - Central Drug Authority Annual Report 2021

DEPARTMENT KEY ACTIVITY KEY ACTIVITY ACHIEVEMENTS MTSF CONFERENCE
DELIVERABLE CONTRIBUTION OUT-COMES RESOLUTION
TO OUTCOME NUMBER
Department of Increase Anti-gangsterism 6HFXULW\ $FWLYL- Anti-gangsterism
6RFLDO HYLGHQFH EDVHG 6WUDWHJ\ ties; Reduction strategy implemented
'HYHORSPHQW SUHYHQWLRQ SURJUDPPHV implemented in drug-market LQ 3URYLQFHV
to target risk groups in UHODWHG YLROHQFH
PXOWLSOH VHWWLQJV
Department of Increase 6RFLDO 6HUYLFH 6RFLDO $FWLYLW\ &DSDFLWDWHG 663ȠV
6RFLDO HYLGHQFH EDVHG Practitioners Reduction of through conducting
'HYHORSPHQW SUHYHQWLRQ SURJUDPPHV FDSDFLWDWHG RQ 6RFLDO 6RFLDO DQG YLUWXDO WUDLQLQJ
to target risk groups in DQG %HKDYLRXU EHKDYLRXUDO
PXOWLSOH VHWWLQJV &KDQJH 6%& SUREOHPV
SURJUDPPH
Department of Enhance multi-sectoral Implement 6RFLDO $FWLYLW\ 2IIHQGHUV
Correctional cooperation to reduce 6XEVWDQFH $EXVH 6WUHQJWKHQHG UHDFKHG
6HUYLFHV GHPDQG IRU GUXJV Programmes by SDUWQHUVKLSV
6RFLDO :RUNHUV ([WHUQDO 6HUYLFH
DQG H[WHUQDO VHUYLFH 3URYLGHUV HQJDJHG LQ
SURYLGHUV UHJLRQV

Department of Ensure adequate 3URYLGH ,QGLYLGXDO Human rights (PSOR\HHV WUHDWHG 9
Correctional capacity, quality, and short-term counsel- DFWLYLW\ IRU DOFRKRO DEXVH RYHU
6HUYLFHV DYDLODELOLW\ RI HYLGHQFH ling to employees ,PSURYHG DFFHVV D WRWDO RI
based treatment and their medical WR YROXQWDU\ VHVVLRQV
SURJUDPV DQG IDFLOLWLHV GHSHQGHQWV treatment for HPSOR\HHV ZHUH
SHRSOH ZLWK 68' treated for drug
DEXVH RYHU
VHVVLRQV

VXSHUYLVRU\
training sessions
were conducted to
($3 3UDFWLWLRQHUV

6RXWK $IULFDQ 'HYHORS D VRFLDO 0RQLWRU +HDOWK $FWLYLW\ VFKRROV LGHQWLˉHG
3ROLFH 6$36 mobilisation /commu- Implementation 7DNH HIIHFWLYH to implement the
QLW\ DGYRFDF\ VWUDWHJ\ RQ RI 6FKRRO 6DIHW\ and practical 6FKRRO 6DIHW\
IRU GHPDQG UHGXFWLRQ Programmes in SURWHFWLYH 3URJUDPPH
LGHQWLˉHG VFKRROV measures to
(substance abuse SUHYHQW SURJUHV-
SUHYHQWLRQ VLRQ WR VHYHUH
programmes to drug use
support school disorders
VDIHW\ through targeted
HDUO\ LQWHUYHQ-
tion for people
DW ULVN

Annual Report 2020/2021 Central Drug Authority 41